Houston, Texas 77004

  • HIV Infections


The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.

Study summary:

HIV-infected patients will be treated with a ritonavir-enhanced Agenerase regimen.


Inclusion Criteria Patients may be eligible for this study if they: - Are 18 years of age or older. - Are HIV-positive. - Have a viral load (level of HIV in the body) of more than 1,000 copies/ml. - Have had more than 12 weeks of prior anti-HIV drug treatment. - Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor. - Are responsive to Agenerase. - Are able to follow study requirements. Exclusion Criteria Patients will not be eligible for this study if they: - Are intolerant to ritonavir (an anti-HIV drug). - Have or have had problems with absorption. - Have liver disease or damage. - Have pancreatic disease or damage. - Have taken any protease inhibitor other than nelfinavir. - Are receiving investigational drugs or devices from another study. - Are pregnant or breast-feeding. - Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide. - Have a bleeding disorder. - Have previously been treated with Agenerase. - Are receiving nonnucleosides.



Primary Contact:


Backup Contact:


Location Contact:

Houston, Texas 77004
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.